The Critical Differences Between Scale Up And Scale Out
Source: Charter Medical
Nurix Therapeutics’ Michael Blackton and Center for Breakthrough Medicines’ John Lee level-set the conversation around scale up and scale out of allogeneic and autologous therapies respectively. From ensuring product safety and efficacy to regulatory issues, Blackton and Lee explain the critical differences between scale up and scale out.
VIEW THE VIRTUAL EVENT!
Log In
Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue.
X
Enter your credentials below to log in. Not yet a member of Cell & Gene? Subscribe today.
Subscribe to Cell & Gene
X
Subscribe to Cell & Gene
Charter Medical
This website uses cookies to ensure you get the best experience on our website. Learn more